JP2020516658A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516658A5 JP2020516658A5 JP2019555957A JP2019555957A JP2020516658A5 JP 2020516658 A5 JP2020516658 A5 JP 2020516658A5 JP 2019555957 A JP2019555957 A JP 2019555957A JP 2019555957 A JP2019555957 A JP 2019555957A JP 2020516658 A5 JP2020516658 A5 JP 2020516658A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- use according
- interleukin
- autoimmune disease
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 9
- 208000023275 Autoimmune disease Diseases 0.000 claims 7
- 230000002163 immunogen Effects 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 230000001506 immunosuppresive effect Effects 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 101710185498 Acetaldehyde dehydrogenase 1 Proteins 0.000 claims 4
- 102000052030 Aldehyde Dehydrogenase 1 Family Human genes 0.000 claims 4
- 102100021723 Arginase-1 Human genes 0.000 claims 4
- 101710129000 Arginase-1 Proteins 0.000 claims 4
- 102100030356 Arginase-2, mitochondrial Human genes 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 4
- 101000792835 Homo sapiens Arginase-2, mitochondrial Proteins 0.000 claims 4
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 claims 4
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims 4
- 101710120843 Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 4
- 102100040062 Indoleamine 2,3-dioxygenase 2 Human genes 0.000 claims 4
- 101710120841 Indoleamine 2,3-dioxygenase 2 Proteins 0.000 claims 4
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 claims 4
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 4
- 102000003814 Interleukin-10 Human genes 0.000 claims 4
- 108090000174 Interleukin-10 Proteins 0.000 claims 4
- 102000004388 Interleukin-4 Human genes 0.000 claims 4
- 108090000978 Interleukin-4 Proteins 0.000 claims 4
- 102000015696 Interleukins Human genes 0.000 claims 4
- 108010063738 Interleukins Proteins 0.000 claims 4
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 claims 4
- 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 claims 4
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 4
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims 4
- 229940076144 interleukin-10 Drugs 0.000 claims 4
- 229940028885 interleukin-4 Drugs 0.000 claims 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 4
- 102100022464 5'-nucleotidase Human genes 0.000 claims 2
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 claims 2
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 claims 2
- 101710088194 Dehydrogenase Proteins 0.000 claims 2
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims 2
- -1 FAS-IL Proteins 0.000 claims 2
- 108010001498 Galectin 1 Proteins 0.000 claims 2
- 102100021736 Galectin-1 Human genes 0.000 claims 2
- 102100031351 Galectin-9 Human genes 0.000 claims 2
- 101710121810 Galectin-9 Proteins 0.000 claims 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims 2
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 claims 2
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims 2
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 2
- 102100027718 Semaphorin-4A Human genes 0.000 claims 2
- 101710199422 Semaphorin-4A Proteins 0.000 claims 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 2
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000001272 nitrous oxide Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000006386 Myelin Proteins Human genes 0.000 claims 1
- 108010083674 Myelin Proteins Proteins 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims 1
- 230000020411 cell activation Effects 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 108091005434 innate immune receptors Proteins 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000005012 myelin Anatomy 0.000 claims 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 1
- 229940045145 uridine Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022082384A JP7444924B2 (ja) | 2017-04-11 | 2022-05-19 | 自己免疫疾患の治療のためのｒｎａ |
| JP2024025246A JP2024059794A (ja) | 2017-04-11 | 2024-02-22 | 自己免疫疾患の治療のためのｒｎａ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2017/058651 | 2017-04-11 | ||
| PCT/EP2017/058651 WO2018188730A1 (en) | 2017-04-11 | 2017-04-11 | Rna for treatment of autoimmune diseases |
| PCT/EP2018/059188 WO2018189193A1 (en) | 2017-04-11 | 2018-04-10 | Rna for treatment of autoimmune diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022082384A Division JP7444924B2 (ja) | 2017-04-11 | 2022-05-19 | 自己免疫疾患の治療のためのｒｎａ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020516658A JP2020516658A (ja) | 2020-06-11 |
| JP2020516658A5 true JP2020516658A5 (enExample) | 2021-09-09 |
| JP7078641B2 JP7078641B2 (ja) | 2022-05-31 |
Family
ID=58632945
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019555957A Active JP7078641B2 (ja) | 2017-04-11 | 2018-04-10 | 自己免疫疾患の治療のためのｒｎａ |
| JP2022082384A Active JP7444924B2 (ja) | 2017-04-11 | 2022-05-19 | 自己免疫疾患の治療のためのｒｎａ |
| JP2024025246A Ceased JP2024059794A (ja) | 2017-04-11 | 2024-02-22 | 自己免疫疾患の治療のためのｒｎａ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022082384A Active JP7444924B2 (ja) | 2017-04-11 | 2022-05-19 | 自己免疫疾患の治療のためのｒｎａ |
| JP2024025246A Ceased JP2024059794A (ja) | 2017-04-11 | 2024-02-22 | 自己免疫疾患の治療のためのｒｎａ |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11701413B2 (enExample) |
| EP (2) | EP3981424A1 (enExample) |
| JP (3) | JP7078641B2 (enExample) |
| KR (2) | KR20240042138A (enExample) |
| CN (2) | CN118161602A (enExample) |
| AU (1) | AU2018253352B2 (enExample) |
| BR (1) | BR112019020667A8 (enExample) |
| CA (1) | CA3059505A1 (enExample) |
| CY (1) | CY1124767T1 (enExample) |
| DK (1) | DK3609529T3 (enExample) |
| ES (1) | ES2893451T3 (enExample) |
| HR (1) | HRP20211559T1 (enExample) |
| HU (1) | HUE056871T2 (enExample) |
| IL (2) | IL269793B (enExample) |
| LT (1) | LT3609529T (enExample) |
| MX (1) | MX2019012144A (enExample) |
| PL (1) | PL3609529T3 (enExample) |
| PT (1) | PT3609529T (enExample) |
| RS (1) | RS62582B1 (enExample) |
| SG (2) | SG10202111163VA (enExample) |
| SI (1) | SI3609529T1 (enExample) |
| SM (1) | SMT202100572T1 (enExample) |
| WO (2) | WO2018188730A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018188730A1 (en) * | 2017-04-11 | 2018-10-18 | Biontech Rna Pharmaceuticals Gmbh | Rna for treatment of autoimmune diseases |
| EP3880174A2 (en) * | 2018-11-12 | 2021-09-22 | Translate Bio, Inc. | Methods for inducing immune tolerance |
| CN118490818A (zh) * | 2020-04-22 | 2024-08-16 | 生物技术欧洲股份公司 | 冠状病毒疫苗 |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| US11161892B1 (en) | 2020-12-07 | 2021-11-02 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| CN115232825B (zh) * | 2021-04-22 | 2023-09-26 | 中国人民解放军军事科学院军事医学研究院 | 一种基于1083骨架的新冠病毒疫苗 |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| IL308571A (en) | 2021-05-26 | 2024-01-01 | Imcyse Sa | Methods of treating or preventing autoimmune diseases |
| EP4355875A1 (en) * | 2021-06-14 | 2024-04-24 | 2seventy bio, Inc. | Single stranded rna purification methods |
| AR126654A1 (es) | 2021-06-29 | 2023-11-01 | Imcyse Sa | Péptidos y métodos para el tratamiento de neuromielitis óptica |
| CN113336862B (zh) * | 2021-07-05 | 2022-03-01 | 广东省科学院动物研究所 | 一种抗多发性硬化的重组蛋白及其制备方法和用途 |
| WO2023030635A1 (en) * | 2021-09-02 | 2023-03-09 | BioNTech SE | Potency assay for therapeutic potential of coding nucleic acid |
| CN118369335A (zh) * | 2022-01-06 | 2024-07-19 | 上海吉量医药工程有限公司 | N1位修饰假尿嘧啶核苷及其在mRNA合成中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7030098B2 (en) * | 1999-03-12 | 2006-04-18 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for treatment of autoimmune disease |
| AU2002952834A0 (en) | 2002-09-16 | 2002-12-05 | The Walter And Eliza Hall Institute Of Medical Research | A method of treating an autoimmune disease |
| PL2578685T3 (pl) * | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
| US9012219B2 (en) * | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| WO2009030254A1 (en) * | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| EP2050814A1 (en) | 2007-10-17 | 2009-04-22 | Txcell | Compositions for treating multiple sclerosis |
| ES2769129T3 (es) | 2009-12-07 | 2020-06-24 | Univ Pennsylvania | Preparaciones de ARN que comprenden ARN modificado purificado para reprogramar células |
| US9778250B2 (en) * | 2011-05-10 | 2017-10-03 | The Brigham And Women's Hospital, Inc. | Detecting inclusion body myositis |
| US20150044244A1 (en) * | 2011-09-30 | 2015-02-12 | Beijing Advanccine Biotechnology Co. Ltd. | Combined facilitator, antigen and dna vaccine for preventing and treating autoimmune diseases |
| DK3421601T3 (da) * | 2011-12-30 | 2020-02-24 | Cellscript Llc | Fremstilling og anvendelse af in-vitro-syntetiseret ssRNA til indføring i pattedyrceller med henblik på at inducere en biologisk eller biokemisk effekt |
| WO2013120498A1 (en) * | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| WO2014160243A1 (en) | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Purification and purity assessment of rna molecules synthesized with modified nucleosides |
| WO2016176330A1 (en) * | 2015-04-27 | 2016-11-03 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| CN106395552B (zh) | 2015-08-03 | 2020-03-17 | 奥的斯电梯公司 | 无绳电梯系统导轨组件 |
| EP3341026B1 (en) * | 2015-08-28 | 2022-01-05 | BioNTech SE | Method for reducing immunogenicity of rna |
| SI3445850T1 (sl) | 2016-04-22 | 2021-12-31 | BioNTech SE | Postopki za zagotavljanje enoverižne RNA |
| WO2018188730A1 (en) * | 2017-04-11 | 2018-10-18 | Biontech Rna Pharmaceuticals Gmbh | Rna for treatment of autoimmune diseases |
-
2017
- 2017-04-11 WO PCT/EP2017/058651 patent/WO2018188730A1/en not_active Ceased
-
2018
- 2018-04-10 PL PL18717580T patent/PL3609529T3/pl unknown
- 2018-04-10 HU HUE18717580A patent/HUE056871T2/hu unknown
- 2018-04-10 KR KR1020247008874A patent/KR20240042138A/ko not_active Withdrawn
- 2018-04-10 SG SG10202111163VA patent/SG10202111163VA/en unknown
- 2018-04-10 KR KR1020197033154A patent/KR102824942B1/ko active Active
- 2018-04-10 DK DK18717580.7T patent/DK3609529T3/da active
- 2018-04-10 CN CN202410206779.6A patent/CN118161602A/zh active Pending
- 2018-04-10 CN CN201880024391.7A patent/CN110719787B/zh active Active
- 2018-04-10 SG SG11201909520V patent/SG11201909520VA/en unknown
- 2018-04-10 LT LTEPPCT/EP2018/059188T patent/LT3609529T/lt unknown
- 2018-04-10 SM SM20210572T patent/SMT202100572T1/it unknown
- 2018-04-10 HR HRP20211559TT patent/HRP20211559T1/hr unknown
- 2018-04-10 WO PCT/EP2018/059188 patent/WO2018189193A1/en not_active Ceased
- 2018-04-10 PT PT187175807T patent/PT3609529T/pt unknown
- 2018-04-10 RS RS20211224A patent/RS62582B1/sr unknown
- 2018-04-10 US US16/500,005 patent/US11701413B2/en active Active
- 2018-04-10 AU AU2018253352A patent/AU2018253352B2/en active Active
- 2018-04-10 ES ES18717580T patent/ES2893451T3/es active Active
- 2018-04-10 JP JP2019555957A patent/JP7078641B2/ja active Active
- 2018-04-10 EP EP21191317.3A patent/EP3981424A1/en active Pending
- 2018-04-10 BR BR112019020667A patent/BR112019020667A8/pt unknown
- 2018-04-10 MX MX2019012144A patent/MX2019012144A/es unknown
- 2018-04-10 CA CA3059505A patent/CA3059505A1/en active Pending
- 2018-04-10 SI SI201830424T patent/SI3609529T1/sl unknown
- 2018-04-10 EP EP18717580.7A patent/EP3609529B1/en active Active
-
2019
- 2019-10-03 IL IL269793A patent/IL269793B/en unknown
-
2021
- 2021-10-06 CY CY20211100867T patent/CY1124767T1/el unknown
-
2022
- 2022-02-28 IL IL290980A patent/IL290980A/en unknown
- 2022-05-19 JP JP2022082384A patent/JP7444924B2/ja active Active
-
2023
- 2023-06-12 US US18/333,273 patent/US20230330198A1/en active Pending
-
2024
- 2024-02-22 JP JP2024025246A patent/JP2024059794A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Legoux et al. | MAIT cell development and functions: the microbial connection | |
| Chen et al. | The role of Th17 cells in inflammatory bowel disease and the research progress | |
| Tordesillas et al. | Mechanisms of oral tolerance | |
| Cheon et al. | Tissue‐resident memory T cells and lung immunopathology | |
| Trompette et al. | Dietary fiber confers protection against flu by shaping Ly6c− patrolling monocyte hematopoiesis and CD8+ T cell metabolism | |
| Chu et al. | Gut microbiota in multiple sclerosis and experimental autoimmune encephalomyelitis: current applications and future perspectives | |
| HRP20211559T1 (hr) | Rnk za liječenje autoimunih bolesti | |
| IL261884A (en) | Compositions of natural extracts and use thereof in methods for preventing or treating diseases | |
| Ongrádi et al. | Factors that may impact on immunosenescence: an appraisal | |
| Peacock et al. | Periodontal and other oral manifestations of immunodeficiency diseases | |
| Palomares et al. | Role of Treg in immune regulation of allergic diseases | |
| Lloyd et al. | Regulatory T cells in asthma | |
| EP3368689B1 (en) | Composition for modulating immune responses by use of immune cell gene signature | |
| US20210254056A1 (en) | Identification and targeted modulation of gene signaling networks | |
| Stojanovska et al. | Oxaliplatin-induced changes in microbiota, TLR4+ cells and enhanced HMGB1 expression in the murine colon | |
| EP3119913B1 (en) | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring | |
| Al Ustwani et al. | Genetics on a WHIM | |
| JP2012515213A5 (enExample) | ||
| WO2017075465A1 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 | |
| Khan et al. | Beyond the complement cascade: insights into systemic immunosenescence and inflammaging in age-related macular degeneration and current barriers to treatment | |
| Zhong et al. | Effects of probiotics, probiotic DNA and the CpG oligodeoxynucleotides on ovalbumin-sensitized Brown-Norway rats via TLR9/NF-κB pathway | |
| Lee et al. | Recombinant Lactococcus lactis Expressing Ling Zhi 8 Protein Ameliorates Nonalcoholic Fatty Liver and Early Atherogenesis in Cholesterol‐Fed Rabbits | |
| Jie et al. | Retinoic acid regulates immune responses by promoting IL-22 and modulating S100 proteins in viral hepatitis | |
| An et al. | Extracellular vesicles in sepsis: pathogenic roles, organ damage, and therapeutic implications | |
| US20240390364A1 (en) | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions |